市場調査レポート

商品コード

1316949

前立腺肥大症治療薬市場：治療クラス、治療法、エンドユーザー別-2023-2030年の世界予測

Benign Prostatic Hyperplasia Treatment Market by Therapeutic Class, Therapy, End User - Cumulative Impact of COVID-19, Russia Ukraine Conflict, and High Inflation - Global Forecast 2023-2030

出版日: 2023年06月12日 | 発行: 360iResearch

| ページ情報: 英文 195 Pages | 納期: 即日から翌営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　詳細はお問い合わせください。

価格

PDF, Excel & Online Access - 1 Year (Single User License)

USD 4,749 746,257円

レポートPDF及びExcelを1名のみがご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペースト可能です。PDFの印刷は何回でも可能ですが、印刷したもののご利用はPDFのご利用範囲に準拠します。購入後1年間、レポートにオンラインでアクセス可能です。

PDF, Excel & Online Access - 1 Year (Up to 5 User License)

USD 5,749 903,397円

レポートPDF及びExcelを5名まで共有ご利用頂けるライセンスです。ご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペースト可能です。PDFの印刷は何回でも可能ですが、印刷したもののご利用はPDFのご利用範囲に準拠します。購入後1年間、レポートにオンラインでアクセス可能です。

PDF, Excel & Online Access - 1 Year (Site License)

USD 6,749 1,060,537円

レポートPDF及びExcelを同一事業所（所在地）内のすべての方でご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペースト可能です。PDFの印刷は何回でも可能ですが、印刷したもののご利用はPDFのご利用範囲に準拠します。購入後1年間、レポートにオンラインでアクセス可能です。

PDF, Excel & Online Access - 1 Year (Enterprise User License)

USD 8,749 1,374,817円

レポートPDF及びExcelを同一企業の全世界の方にご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペースト可能です。PDFの印刷は何回でも可能ですが、印刷したもののご利用はPDFのご利用範囲に準拠します。購入後1年間、レポートにオンラインでアクセス可能です。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=157.14円

ご注意事項 :

本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

前立腺肥大症治療薬の世界市場は大きく成長すると予測され、2023年には85億8,495万米ドルが予測され、CAGRは6.96%、2030年には137億6,732万米ドルに達すると予測されています。

FPNVポジショニング・マトリックス

FPNVポジショニングマトリックスは世界の前立腺肥大症治療薬市場を評価するために不可欠です。事業戦略と製品満足度の主要指標を調査することで、ベンダーの包括的な評価を提供し、ユーザーは特定のニーズに基づいた情報をもとに意思決定を行うことができます。この高度な分析により、ベンダーは成功の度合いが異なる4つの象限に整理されます：フォアフロント（F）、パスファインダー（P）、ニッチ（N）、バイタル（V）です。

市場シェア分析

市場シェア分析では、特定の市場領域におけるベンダーの現状を洞察することができます。全体的な収益、顧客基盤、その他の主要指標に対するベンダーの貢献度を比較することで、企業が市場シェアを争う際に、自社の業績や直面している状況をより深く理解することができます。また、本分析では、調査した基準年において、特定のセクターがどの程度競合しているのか、蓄積、断片化の優位性、合併の特徴についても明らかにしています。

本レポートは、以下のポイントに関する洞察を提供します：

1.市場の浸透度：主要企業が提供する市場に関する包括的な情報を提供します。

2.市場の発展：有利な新興市場に関する詳細情報を提供し、市場の成熟セグメントにおける浸透度を分析します。

3.市場の多様化：新製品の上市、未開発地域、最近の開発、投資に関する詳細情報を提供します。

4.市場の動向：COVID-19、ロシア・ウクライナ紛争、高インフレの累積的な影響を包括的に理解することができます。

5.競合の評価と情報：主要企業の市場シェア、戦略、製品、認証、規制状況、特許状況、製造能力を網羅的に評価します。

6.製品開発およびイノベーション：将来技術、研究開発活動、画期的な製品開発に関する知的洞察を提供します。

本レポートは、以下のような質問にお答えします：

1.前立腺肥大症治療薬の世界市場規模および予測は？

2.予測期間中、世界の前立腺肥大症治療薬市場を形成するCOVID-19の阻害要因と影響は？

3.前立腺肥大症治療薬の世界市場において予測期間中に投資すべき製品/セグメント/アプリケーション/分野は？

4.前立腺肥大症治療薬の世界市場における競争戦略は？

5.前立腺肥大症治療薬の世界市場における技術動向と規制の枠組みは？

6.前立腺肥大症治療薬の世界市場における主要ベンダーの市場シェアは？

7.前立腺肥大症治療薬の世界市場への参入には、どのような形態や戦略的な動きが適していると考えられるか？

市場力学
- 促進要因
  - 前立腺肥大症の増加
  - 手術、薬剤および治療の承認に対する有利な償還
  - ヘルスケアインフラの改善に対する政府の投資
- 抑制要因
  - BPH治療に関連した副作用
- 機会
  - 前立腺肥大症に対する低侵襲治療法の登場
  - 前立腺肥大症に関する研究開発が進行中
- 課題
  - 治療効果の欠如
市場動向
COVID-19の累積的な影響
ロシア・ウクライナ紛争の累積的影響
高インフレの累積的影響
ポーターのファイブフォース分析
バリューチェーンとクリティカルパス分析
規制の枠組み
顧客のカスタマイズ

第6章前立腺肥大症治療薬市場セラピークラス別

5-αレダクターゼ阻害剤
アルファブロッカー
ホスホジエステラーゼ-5阻害剤

第7章前立腺肥大症治療薬市場セラピー別

併用薬物療法
単一薬物療法

第8章前立腺肥大症治療薬市場：エンドユーザー別

外来手術センター
病院
専門クリニック

第9章南北アメリカの前立腺肥大症治療薬市場

アルゼンチン
ブラジル
カナダ
メキシコ
米国

第10章アジア太平洋地域の前立腺肥大症治療薬市場

オーストラリア
中国
インド
インドネシア
日本
マレーシア
フィリピン
シンガポール
韓国
台湾
タイ
ベトナム

第11章欧州・中東・アフリカの前立腺肥大症治療薬市場

デンマーク
エジプト
フィンランド
フランス
ドイツ
イスラエル
イタリア
オランダ
ナイジェリア
ノルウェー
ポーランド
カタール
ロシア
サウジアラビア
南アフリカ
スペイン
スウェーデン
スイス
トルコ
アラブ首長国連邦
英国

第12章競合情勢

FPNVポジショニングマトリクス
市場シェア分析：主要企業別
競合シナリオ分析：主要企業別

第13章掲載企業一覧

第14章付録

ディスカッションガイド
ライセンスと価格について

図表

LIST OF FIGURES

FIGURE 1. BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET RESEARCH PROCESS
FIGURE 2. BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, 2022 VS 2030
FIGURE 3. BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2022 VS 2030 (%)
FIGURE 5. BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPY, 2022 VS 2030 (%)
FIGURE 6. BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2022 VS 2030 (%)
FIGURE 7. BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY REGION, 2022 VS 2030 (%)
FIGURE 8. BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET DYNAMICS
FIGURE 9. BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 10. BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPY, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 11. BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 12. AMERICAS BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 13. UNITED STATES BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY STATE, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 14. ASIA-PACIFIC BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 15. EUROPE, MIDDLE EAST & AFRICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 16. BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET, FPNV POSITIONING MATRIX, 2022
FIGURE 17. BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SHARE, BY KEY PLAYER, 2022

LIST OF TABLES

TABLE 1. BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2022
TABLE 3. BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 5. BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITOR, BY REGION, 2018-2030 (USD MILLION)
TABLE 6. BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY ALPHA-BLOCKER, BY REGION, 2018-2030 (USD MILLION)
TABLE 7. BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PHOSPHODIESTERASE-5 INHIBITOR, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 9. BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY COMBINATION DRUG THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MONO DRUG THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 12. BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. AMERICAS BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 16. AMERICAS BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 17. AMERICAS BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 18. AMERICAS BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 19. ARGENTINA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 20. ARGENTINA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 21. ARGENTINA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 22. BRAZIL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 23. BRAZIL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 24. BRAZIL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 25. CANADA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 26. CANADA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 27. CANADA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 28. MEXICO BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 29. MEXICO BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 30. MEXICO BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 31. UNITED STATES BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 32. UNITED STATES BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 33. UNITED STATES BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 34. UNITED STATES BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 35. ASIA-PACIFIC BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 36. ASIA-PACIFIC BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 37. ASIA-PACIFIC BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 38. ASIA-PACIFIC BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 39. AUSTRALIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 40. AUSTRALIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 41. AUSTRALIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 42. CHINA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 43. CHINA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 44. CHINA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 45. INDIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 46. INDIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 47. INDIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 48. INDONESIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 49. INDONESIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 50. INDONESIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 51. JAPAN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 52. JAPAN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 53. JAPAN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 54. MALAYSIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 55. MALAYSIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 56. MALAYSIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 57. PHILIPPINES BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 58. PHILIPPINES BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 59. PHILIPPINES BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 60. SINGAPORE BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 61. SINGAPORE BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 62. SINGAPORE BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 63. SOUTH KOREA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 64. SOUTH KOREA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 65. SOUTH KOREA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 66. TAIWAN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 67. TAIWAN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 68. TAIWAN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 69. THAILAND BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 70. THAILAND BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 71. THAILAND BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 72. VIETNAM BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 73. VIETNAM BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 74. VIETNAM BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 75. EUROPE, MIDDLE EAST & AFRICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 76. EUROPE, MIDDLE EAST & AFRICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 77. EUROPE, MIDDLE EAST & AFRICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 78. EUROPE, MIDDLE EAST & AFRICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 79. DENMARK BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 80. DENMARK BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 81. DENMARK BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 82. EGYPT BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 83. EGYPT BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 84. EGYPT BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 85. FINLAND BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 86. FINLAND BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 87. FINLAND BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 88. FRANCE BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 89. FRANCE BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 90. FRANCE BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 91. GERMANY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 92. GERMANY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 93. GERMANY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 94. ISRAEL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 95. ISRAEL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 96. ISRAEL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 97. ITALY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 98. ITALY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 99. ITALY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 100. NETHERLANDS BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 101. NETHERLANDS BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 102. NETHERLANDS BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 103. NIGERIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 104. NIGERIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 105. NIGERIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 106. NORWAY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 107. NORWAY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 108. NORWAY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 109. POLAND BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 110. POLAND BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 111. POLAND BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 112. QATAR BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 113. QATAR BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 114. QATAR BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 115. RUSSIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 116. RUSSIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 117. RUSSIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 118. SAUDI ARABIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 119. SAUDI ARABIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 120. SAUDI ARABIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 121. SOUTH AFRICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 122. SOUTH AFRICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 123. SOUTH AFRICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 124. SPAIN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 125. SPAIN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 126. SPAIN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 127. SWEDEN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 128. SWEDEN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 129. SWEDEN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 130. SWITZERLAND BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 131. SWITZERLAND BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 132. SWITZERLAND BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 133. TURKEY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 134. TURKEY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 135. TURKEY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 136. UNITED ARAB EMIRATES BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 137. UNITED ARAB EMIRATES BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 138. UNITED ARAB EMIRATES BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 139. UNITED KINGDOM BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 140. UNITED KINGDOM BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 141. UNITED KINGDOM BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 142. BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET, FPNV POSITIONING MATRIX, 2022
TABLE 143. BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SHARE, BY KEY PLAYER, 2022
TABLE 144. BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET LICENSE & PRICING

Product Code: MRR-437D45958490

The Global Benign Prostatic Hyperplasia Treatment Market is forecasted to grow significantly, with a projected USD 8,584.95 million in 2023 at a CAGR of 6.96% and expected to reach a staggering USD 13,767.32 million by 2030.

The Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and High Inflation is expected to have significant long-term effects on the Global Benign Prostatic Hyperplasia Treatment Market. The ongoing research considers the changes in consumer behavior, supply chain disruptions, and government interventions caused by the pandemic. Similarly, the report considers the ongoing political and economic uncertainty in Eastern Europe caused by the Russia-Ukraine Conflict and its potential implications for demand-supply balances, pressure on pricing variants, and import/export and trading. Additionally, the report addresses the impact of High Inflation on the global economy and details fiscal policies measuring and reducing its effects on demand, supply, cash flow, and currency exchange.

Market Segmentation & Coverage:

This research report categorizes the Global Benign Prostatic Hyperplasia Treatment Market in order to forecast the revenues and analyze trends in each of following sub-markets:

Based on Therapeutic Class, market is studied across 5-Alpha Reductase Inhibitor, Alpha-Blocker, and Phosphodiesterase-5 Inhibitor. The 5-Alpha Reductase Inhibitor is projected to witness significant market share during forecast period.

Based on Therapy, market is studied across Combination Drug Therapy and Mono Drug Therapy. The Combination Drug Therapy is projected to witness significant market share during forecast period.

Based on End User, market is studied across Ambulatory Surgical Centers, Hospitals, and Specialty Clinics. The Hospitals is projected to witness significant market share during forecast period.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom. The Americas commanded largest market share of 38.75% in 2022, followed by Europe, Middle East & Africa.

Market Statistics:

The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make well-informed decisions. In this report, 2018 to 2021 are considered as historical years, 2022 is base year, 2023 is estimated year, and years from 2024 to 2030 are considered as forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix is essential for assessing the Global Benign Prostatic Hyperplasia Treatment Market. It provides a comprehensive evaluation of vendors by examining key metrics within Business Strategy and Product Satisfaction, allowing users to make informed decisions based on their specific needs. This advanced analysis then organizes these vendors into four distinct quadrants, which represent varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital(V).

Market Share Analysis:

The Market Share Analysis offers an insightful look at the current state of vendors in a particular market space. By comparing vendor contributions to overall revenue, customer base, and other key metrics, we can give companies a greater understanding of their performance and what they are up against when competing for market share. The analysis also sheds light on just how competitive any given sector is about accumulation, fragmentation dominance, and amalgamation traits over the base year period studied.

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players

2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes penetration across mature segments of the markets

3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments

4. Market Trends: Provides comprehensive understanding of the Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and the High Inflation

5. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players

6. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the Global Benign Prostatic Hyperplasia Treatment Market?

2. What are the inhibiting factors and impact of COVID-19 shaping the Global Benign Prostatic Hyperplasia Treatment Market during the forecast period?

3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Benign Prostatic Hyperplasia Treatment Market?

4. What is the competitive strategic window for opportunities in the Global Benign Prostatic Hyperplasia Treatment Market?

5. What are the technology trends and regulatory frameworks in the Global Benign Prostatic Hyperplasia Treatment Market?

6. What is the market share of the leading vendors in the Global Benign Prostatic Hyperplasia Treatment Market?

7. What modes and strategic moves are considered suitable for entering the Global Benign Prostatic Hyperplasia Treatment Market?

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

4.1. Introduction
4.2. Benign Prostatic Hyperplasia Treatment Market, by Therapeutic Class, 2022 vs 2030
4.3. Benign Prostatic Hyperplasia Treatment Market, by Therapy, 2022 vs 2030
4.4. Benign Prostatic Hyperplasia Treatment Market, by End User, 2022 vs 2030
4.5. Benign Prostatic Hyperplasia Treatment Market, by Region, 2022 vs 2030

5. Market Insights

5.1. Market Dynamics
- 5.1.1. Drivers
  - 5.1.1.1. Growth in cases of benign prostatic hyperplasia
  - 5.1.1.2. Favorable reimbursement for surgeries and drug and treatemnt approvals
  - 5.1.1.3. Government investments in improving healthcare infrastructure
- 5.1.2. Restraints
  - 5.1.2.1. Side-effects related to BPH treatment
- 5.1.3. Opportunities
  - 5.1.3.1. Emergence of minimally invasive treatments for benign prostatic hyperplasia
  - 5.1.3.2. Ongoing research & development regarding benign prostatic hyperplasia
- 5.1.4. Challenges
  - 5.1.4.1. Lack of efficacy of treatments
5.2. Market Trends
5.3. Cumulative Impact of COVID-19
5.4. Cumulative Impact of Russia-Ukraine Conflict
5.5. Cumulative Impact of High Inflation
5.6. Porter's Five Forces Analysis
- 5.6.1. Threat of New Entrants
- 5.6.2. Threat of Substitutes
- 5.6.3. Bargaining Power of Customers
- 5.6.4. Bargaining Power of Suppliers
- 5.6.5. Industry Rivalry
5.7. Value Chain & Critical Path Analysis
5.8. Regulatory Framework
5.9. Client Customization

6. Benign Prostatic Hyperplasia Treatment Market, by Therapeutic Class

6.1. Introduction
6.2. 5-Alpha Reductase Inhibitor
6.3. Alpha-Blocker
6.4. Phosphodiesterase-5 Inhibitor

7. Benign Prostatic Hyperplasia Treatment Market, by Therapy

7.1. Introduction
7.2. Combination Drug Therapy
7.3. Mono Drug Therapy

8. Benign Prostatic Hyperplasia Treatment Market, by End User

8.1. Introduction
8.2. Ambulatory Surgical Centers
8.3. Hospitals
8.4. Specialty Clinics

9. Americas Benign Prostatic Hyperplasia Treatment Market

9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States

10. Asia-Pacific Benign Prostatic Hyperplasia Treatment Market

10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam

11. Europe, Middle East & Africa Benign Prostatic Hyperplasia Treatment Market

11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom

前立腺肥大症治療薬市場：治療クラス、治療法、エンドユーザー別-2023-2030年の世界予測

Benign Prostatic Hyperplasia Treatment Market by Therapeutic Class, Therapy, End User - Cumulative Impact of COVID-19, Russia Ukraine Conflict, and High Inflation - Global Forecast 2023-2030

FPNVポジショニング・マトリックス

市場シェア分析

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

第6章 前立腺肥大症治療薬市場セラピークラス別

第7章 前立腺肥大症治療薬市場セラピー別

第8章 前立腺肥大症治療薬市場：エンドユーザー別

第9章 南北アメリカの前立腺肥大症治療薬市場

第10章 アジア太平洋地域の前立腺肥大症治療薬市場

第11章 欧州・中東・アフリカの前立腺肥大症治療薬市場

第12章 競合情勢

第13章 掲載企業一覧

第14章 付録